Pierre Fabre

60 articles about Pierre Fabre

• Biomax Informatics Collaborates With Pierre Fabre To Provide A Research Environment To Support Therapeutic Antibody Development

  6/18/2015

• AbCheck s.r.o. And Pierre Fabre Enter Into Strategic Research Partnership

  6/17/2015

• Pierre Fabre Release: A phase 2/3 Clinical Data Published In The NEJM Confirms Positive Safety-Efficacy Profile For First Pediatric Treatment For Infantile Hemangioma

  2/20/2015

• Drugmaker Pierre Fabre To Slash 551 R&D Jobs By 2016

  12/10/2014

• Pierre Fabre Obtains European Commission Marketing Authorization For Hemangiol®, The First And Only Drug Approved For The Treatment Of Proliferating Infantile Hemangioma

  5/5/2014

• Pierre Fabre Selects Pierre Fabre Doccompliance To Manage Quality Documents Across Entire Organization

  4/28/2014

• Pierre Fabre Obtains FDA Approval To Market Hemangeo™ For The Treatment Of Infantile Hemangioma

  3/18/2014

• Aurigene Discovery Technologies Limited And Pierre Fabre Announce A Licensing Agreement For A New Cancer Therapeutic In Immuno-Oncology : AUNP12, An Immune Checkpoint Modulator Targeting The PD-1 Pathway

  2/12/2014

• Forest Laboratories, Inc. and Pierre Fabre Grab FDA OK on Depression Drug

  7/30/2013

• ADVENTRX Pharmaceuticals Inc. and Pierre Fabre Announce Manufacturing Agreement for ANX-188 Drug Substance

  6/12/2012

• Pierre Fabre Selects Dassault Systèmes SolidWorks Corp.' Version 6 Platform to Deploy Next-Generation PLM for Life Sciences

  11/22/2011

• Sales of Dermo-Cosmetics on the Internet: Ruling by the EU Court of Justice Allows Pierre Fabre to Defend Their Right to an Individual Exemption

  10/13/2011

• MediGene AG and Pierre Fabre Sign Agreement for the Commercialization of Veregen(R) in Mexico, Central America, Venezuela and Colombia

  2/22/2011

• Forest Laboratories, Inc. and Pierre Fabre Announce Topline Phase III Results from a Study of Levomilnacipran for the Treatment of Major Depressive Disorder; Drug Fails to Meet Statistical Significance

  1/20/2011

• Pierre Fabre's Bladder Cancer Drug, Javlor too Costly for National Health Service, National Institute for Clinical Excellence (NICE) Says

  11/23/2010

• Pierre Fabre to Strengthen Partnership with Cegedim Dendrite

  3/29/2010

• Abbott Laboratories (JOBS) Enters Into Cancer Pact with France's Pierre Fabre; Abbott to Pay $25 Million

  2/2/2010

• Forest Laboratories, Inc. Gains Rights to Pierre Fabre Anti-depressant for $75 Million

  12/22/2008

• Pierre Fabre Donates the Majority Equity Interest in his Company to his Foundation

  9/5/2008

• Pierre Fabre Acquires Over-The-Counter Business Of UCB Group In France, Benelux, Switzerland And Greece

  1/8/2007